Inotersen · Tegsedi
RNA / oligonucleotide
Evidence outlook · regulatory status
US approval withdrawn: Transthyretin Amyloidosis with Polyneuropathy (FDA, approved 2018-10-05)
The FDA approved this product and later withdrew the approval, so it has no current US approval. The withdrawal took effect on 2025-02-14. The applicants told the FDA the products were no longer marketed and asked for the approvals to be withdrawn. Approval is withdrawn as of February 14, 2025. Approvals outside the US are listed below. The trials below are the product's evidence history.
Also approved (1)
- Stage 1 or stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis (hATTR)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01737398 NCT01737398 · Transthyretin Amyloidosis with Polyneuropathy This was a randomized, quadruple-blind, placebo-controlled trial in 172 patients. Both co-primary endpoints, a validated neuropathy impairment score and a quality-of-life questionnaire, showed statistically significant benefit with inotersen versus placebo at week 66. Registry: NCT01737398 | 2/3 | Change From Baseline In The Modified Neuropathy Impairment Score (mNIS) +7 Composite Score at Week 66 (Baseline and Week 66); Change From Baseline In The Norfolk Quality Of Life Diabetic Neuropathy (QoL-DN) Questionnaire at Week 66 (Baseline and Week 66) 2017-03-03 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (1)
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Competitive landscape
Other Transthyretin (TTR) drugs
Acoramidis, Eplontersen, Patisiran, Vutrisiran, Cliramitug and 3 more. Compare all 9 Transthyretin (TTR) drugs
This mechanism is crowded: 8 other tracked programmes target it, 4 of them ahead of this one.
This drug's own stage for Transthyretin Amyloidosis with Polyneuropathy: US approval withdrawn. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Inotersen (Tegsedi): this drug | US approval withdrawn | RNA / oligonucleotide | Transthyretin (TTR) | Reliable signal | No reviewed efficacy summary in this indication | |
| Acoramidis (Attruby) | Approved(overall) | Small molecule | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Eplontersen (Wainua) | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Weak signal | No reviewed efficacy summary in this indication | |
| Patisiran (ONPATTRO) | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Reliable signal | NCT01960348: Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) | |
| Vutrisiran (AMVUTTRA) | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Partial signal | NCT03759379: Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43) | |
| Cliramitug | Phase 3(overall) | Monoclonal antibody | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Coramitug | Phase 3(overall) | Monoclonal antibody | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Nexiguran Ziclumeran | Phase 3(overall) | Gene therapy / editing | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Nucresiran | Phase 3 | RNA / oligonucleotide | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent